Real-world data for frontline palbociclib indicate that the positive progression-free survival data observed with the CDK4/6 inhibitor in the pivotal PALOMA-2 trial would likely translate to an overall survival benefit in... Read More >>
Overexpression of pro-survival BCL-2 family regulator proteins is an important driver of resistance to cell death in acute myeloid leukemia (AML). Accordingly, the BCL-2 pathway has emerged as an attractive research target for novel therapies.
Data and analysis shared at the 17th International Myeloma Workshop show that anti-BCMA directed treatments, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates have the potential to revolutionize the multiple myeloma treatment paradigm.
Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now